Biologics as countermeasures for acute radiation syndrome: where are we now?

Bibliography

• Hall EJ, Giaccia AJ. Radiobiology for the Radiobiologist. 6th edition. Lippincott Williams and Wilkins; Philadelphia, PA: 2006
   Google Scholar
• Singh VK, Newman VL, Romaine PL, et al. Radiation countermeasure agents: an update (2011 – 2014). Expert Opin Ther Pat 2014;24(11):1229-55
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Guidance for Industry: product Developoment Under the Animal Rule. 2014. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM399217.pdf [Last accessed 2014]
   Google Scholar
• Singh VK, Newman VL, Seed TM. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Cytokine 2014;71(1):22-37
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA Advisory Committee Briefing Document: a Joint Meeting of the Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/MedicalImagingDrugsAdvisoryCommittee/UCM350151.pdf [Last accessed 5 February 2014]
   Google Scholar
• Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320(5873):226-30
   PubMed Web of Science ®Google Scholar
• Cleveland BioLabs, Inc. 2014. Available from: http://www.cbiolabs.com/ [Last accessed 2014]
   Google Scholar
• Krivokrysenko VI, Shakhov AN, Singh VK, et al. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther 2012;343(2):497-508
   PubMed Web of Science ®Google Scholar
• Gluzman-Poltorak Z, Mendonca SR, Vainstein V, et al. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J Hematol Oncol 2014;7:31
   PubMed Web of Science ®Google Scholar
• Neumedicines 2014. Available from: http:// www.neumedicines.com/ [Last accessed 27 October 2014]
   Google Scholar
• Singh VK, Christensen J, Fatanmi OO, et al. Myeloid Progenitors: a radiation countermeasure that is effective when initiated days after irradiation. Radiat Res 2012;177(6):781-91
   PubMed Web of Science ®Google Scholar
• Cellerant Therapeutics. 2013. Available from: http://www.cellerant.com/ [Last] [accessed 26 September 2013]
   Google Scholar
• Rotolo J, Stancevic B, Zhang J, et al. Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice. J Clin Invest 2012;122(5):1786-90
   PubMed Web of Science ®Google Scholar
• Casey-Sawicki K, Zhang M, Kim S, et al. A basic fibroblast growth factor analog for protection and mitigation against acute radiation syndromes. Health Phys 2014;106(6):704-12
   PubMed Web of Science ®Google Scholar
• Zhou D, Deoliveira D, Kang Y, et al. Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation. Int J Radiat Oncol Biol Phys 2013;85(4):1141-8
   PubMed Web of Science ®Google Scholar
• Hao J, Sun L, Huang H, et al. Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. Radiat Res 2004;162(2):157-63
   PubMed Web of Science ®Google Scholar
• Drouet M, Mourcin F, Grenier N, et al. Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis. Blood 2004;103(3):878-85
   PubMed Web of Science ®Google Scholar
• Drouet M, Grenier N, Herodin F. Revisiting emergency anti-apoptotic cytokinotherapy: erythropoietin synergizes with stem cell factor, FLT-3 ligand, trombopoietin and interleukin-3 to rescue lethally-irradiated mice. Eur Cytokine Netw 2012;23(2):56-63
   PubMed Web of Science ®Google Scholar
• Hankey KG, Farese AM, Gibbs AM, et al. Pegfilgrastim administration significantly improves survival in an LD50/60 model of total body irradiation (TBI) in nonhuman primates (NHP). 59th Annual Meeting of the Radiatrion Research Society; New Orleans, LA; 2013. p. 318
   Google Scholar
• Farese AM, Cohen MV, Katz BP, et al. Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res 2013;179(1):89-100
   PubMed Web of Science ®Google Scholar
• Dainiak N, Gent RN, Carr Z, et al. First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. Disaster Med Public Health Prep 2011;5(3):202-12
   PubMed Web of Science ®Google Scholar